Genitourinary Cancers

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses cytoreductive nephrectomy for patients with renal cell carcinoma (RCC).

The European Commission has approved tivozanib for the treatment of patients with advanced renal cell carcinoma.

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer.

Michael B. Atkins, MD, discusses the latest IMmotion150 findings and additional developments with immunotherapy in mRCC.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

The guidelines provide evidence-based recommendations on staging, neoadjuvant and adjuvant chemotherapy, radical cystectomy, urinary diversion, perioperative surgical management, and pelvic lymphadenectomy.

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the role of radical nephrectomy according to the guidelines for patients with renal cell carcinoma (RCC).

Ketan K. Badani, MD, discusses the benefits of robotic surgery in RCC and use of the technique among urologists.

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses the adoption of robotic surgery in kidney cancer.

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the challenges with MRI in prostate cancer.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).